Product Highlight - AJOVY

The only licensed anti-CGRP to offer flexible quarterly and monthly dosing¹

• AJOVY is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month¹
• More migraine-free days vs. placebo, with results seen as early as Week 1^1–3
• A well-tolerated treatment choice^1–3
• Flexible quarterly or monthly dosing, with or without concomitant oral preventatives¹

References:
1. AJOVY 225 mg solution for injection in pre-filled syringe – Summary of Product Characteristics. Teva Hong Kong, July 2021.
2. Dodick DW et al. JAMA. 2018; 319(19): 1999-2008.
3. Silberstein SD et al. N Engl J Med. 2017; 377(22): 2113-2122.

AJO-HK-00008 Nov 2023